Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used?

Mauro, Michael J.; Maziarz, Richard T.
March 2006
Mayo Clinic Proceedings;Mar2006, Vol. 81 Issue 3, p404
Academic Journal
Hematopoletic stem cell transplantation has been a cornerstone of therapy for chronic myelogenous leukemia (CML) for more than 15 years and is still a standard treatment option for patients with CML. The advent of imatinib mesylate, an inhibitor of the molecular defect driving CML, the BCR-ABL tyrosine kinase, has rewritten treatment algorithms for this disease and has shifted focus away from allografting. Despite advances in stem cell transplantation, such as broader availability with the use of modified conditioning regimens, use of allografting has diminished. Also, the nearly universal patient exposure to imatinib or other kinase inhibitors before transplantation may affect the biology of the disease that is currently being treated with an allograft and ultimately may affect outcomes. Exceedingly high rates of meaningful and stable response with longer follow-up continue to drive enthusiasm for imatinib use, and understanding of resistance mechanisms has driven rapid investigation of second-generation tyrosine kinase inhibitors to address imatinib failure and suboptimal response. In most patients, imatinib reduces CML to a minimal residual disease state in which options to further deepen remission, such as immunotherapy, are sought; monitoring techniques and interpretation of response advance in parallel to meet demands; and uncertainty remains as a new natural history of CML is defined in an era of kinase inhibitor therapy. This review summarizes the state of transplant and nontransplant therapy for CML and discusses the decision making for patients with an aim to optimize the use of our best therapies for CML in an era of uncertainty.


Related Articles

  • Successful Pregnancy and Delivery in a Patient with Chronic Myeloid Leukemia while on Dasatinib Therapy. Conchon, Monika; Sanabani, Sabri S.; Serpa, Mariana; Novaes, Mafalda M. Y.; Nardinelli, Luciana; Ferreira, Patrícia B.; Dorliac-Llacer, Pedro Enrique; Bendit, Israel // Advances in Hematology;2010, Vol. 2010, p1 

    Here we report the case of an 18-year-old woman with chronic myeloid leukemia (CML) who became pregnant while undergoing treatment with dasatinib. Before pregnancy, she received imatinib mesylate therapy but could not tolerate the treatment. The regimen was then changed to dasatinib at a dose of...

  • Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Ruiz-Argüelles, G. J.; Tarin-Arzaga, L. C.; Gonzales-Carillo, M. L.; Gutierrez-Riveroll, K. I.; Rangel-Malo, R.; Gutiérrez-Aguirre, C. H.; Cantú-Rodríguez, O. G.; Gómez-Almaguer, D.; Giralt, S. // Bone Marrow Transplantation;Jul2008, Vol. 42 Issue 1, p23 

    A total of 72 patients with Ph-positive CML in first chronic phase were followed during a 6-year period in two different institutions in México. Among them, 22 were given a reduced-intensity allogeneic SCT, whereas 50 were given a tyrosine kinase inhibitor (TKI), mainly imatinib mesylate. The...

  • Allogeneic stem cell transplantation for chronic myeloid leukemia–status in 2007. Goldman, J. M. // Bone Marrow Transplantation;Aug2008 Supplement, Vol. 42, pS11 

    Whereas until 2000 allo-SCT was the recommended treatment for all new patients with CML who were eligible on grounds of age and donor availability, approaches to initial therapy have ch‘anged very substantially since the introduction of imatinib mesylate. Today topical questions are (1)...

  • Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Suttorp, M. // Bone Marrow Transplantation;Oct2008 Supplement, Vol. 42, pS40 

    Allogeneic haematopoietic SCT (HSCT) induces CRs in most patients with CML. With the excellent short-term treatment results induced by imatinib (IMA), attitudes have changed and only a minority of children are now transplanted upfront. This review addresses the role of IMA in children with CML,...

  • The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire. Koffi, K. G.; Nanho, D. C.; N'dathz, E.; Kouehion, P.; Dissieka, R.; Attia, A.; Mozard, K.; Tolo, A.; Boidy, K.; Meité, N.; Ayemou, R.; Sekongo, M.; Tea, N.; Sanogo, I. // Advances in Hematology;2010, Vol. 2010, p1 

    Imatinib mesylate, showed encouraging activity in chronic myelogenous leukemia. However, there are few data regarding his efficacy and response monitoring in Sub-Saharan African patients. Our objective was to assess response to imatinib mesylate (Glivec) in Côte d'Ivoire patients with newly...

  • A Critical History of Chromic Myeloid Leukemia. Baccarani, Michele; Pane, Fabrizio // Mediterranean Journal of Hematology & Infectious Diseases;2014, Vol. 6 Issue 1, p1 

    The author reflects on various developments in treatment of chronic myeloid leukemia (CML), a cancer of white blood cells (WBCs). Topics discussed include development of targeted treatments for CML such as by targeting the tyrosine kinase inhibitors (TKIs), history of treatment of CML such as by...


    Chronic myeloid leukemia (CML) is a common marrow stem cell neoplasm characterized by the presence of the Philadelphia (Ph) chromosome in more than 90% of patients. Studies have shown that CML can be associated with various other cytogenetic abnormalities. 5-10% of these cases can show complex...

  • Alopecia areata after HLA-identical BMT from an affected, sibling donor. Nadeem, S; Hymes, S; Kebriaei, P; Abruzzo, L; Curry, J L; Duvic, M // Bone Marrow Transplantation;Apr2014, Vol. 49 Issue 4, p592 

    Two case studies are presented such as a 48-year-old white man with chronic myelogenous leukemia (CML) and a 55-year-old white female with acute myeloid leukemia (AML). The patients have developed alopecia areata after receiving an allogeneic stem cell transplantation. It notes that alopecia...

  • Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Scherr, M; Elder, A; Battmer, K; Barzan, D; Bomken, S; Ricke-Hoch, M; Schröder, A; Venturini, L; Blair, H J; Vormoor, J; Ottmann, O; Ganser, A; Pich, A; Hilfiker-Kleiner, D; Heidenreich, O; Eder, M // Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p554 

    Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the development of novel treatment strategies. As the known oncomir, miR-17∼92, is regulated by BCR-ABL fusion in chronic myeloid...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics